Clinical Trials Browser

Triple Negative Breast Neoplasms × camrelizumab × Clear all

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Phase 2 Recruiting

369 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2 Not yet recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 3 Completed

441 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

Phase 3 Recruiting

424 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

139 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05749588 2023-11-14

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase 2 Recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Phase 1/2 Unknown

125 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Phase 2 Unknown

58 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05670925 2023-02-28

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Phase 2 Unknown

46 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Phase 2 Unknown

46 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04676997 2020-12-21

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Phase 2 Unknown

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04481763 2020-07-22

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Phase 1/2 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Phase 1/2 Unknown

39 enrolled

Breast

Triple Negative Breast Neoplasms